Download PDF
Der Klinikarzt 2018; 47(09): 418-425
DOI: 10.1055/a-0697-7534
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Multiples Myelom

Diagnostik, Therapie und neue Entwicklungen
Amelie Boquoi
Klinik für Hämatologie, Onkologie und klinische Immunologie, Universitätsklinikum Düsseldorf, Düsseldorf
,
Judith Strapatsas
Klinik für Hämatologie, Onkologie und klinische Immunologie, Universitätsklinikum Düsseldorf, Düsseldorf
,
Roland Fenk
Klinik für Hämatologie, Onkologie und klinische Immunologie, Universitätsklinikum Düsseldorf, Düsseldorf
,
Rainer Haas
Klinik für Hämatologie, Onkologie und klinische Immunologie, Universitätsklinikum Düsseldorf, Düsseldorf
› Author Affiliations
Further Information

Publication History

Publication Date:
19 September 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Ergebnisse molekularbiologischer Untersuchungen mittels „Whole Genome Sequencing“ haben unser pathophysiologisches Verständnis des Multiplen Myeloms grundlegend verändert. Wir wissen heute, dass der maligne Plasmazellklon keiner linearen Entwicklung folgt, sondern bereits zu Beginn der Erkrankung multiple Klone vorhanden sind, die aufgrund ihrer individuellen Dynamik und Expansion die klonale Komposition und damit den Verlauf der Erkrankung bestimmen. Klinisch leitet sich aus dieser Erkenntnis die Notwendigkeit zur Durchführung von Kombinationstherapien mit synergistischen Wirkungsmechanismen ab, um Überleben und Wachstum möglichst vieler Klone zu verhindern. Der medizinische Fortschritt hat in den letzten Jahren zur Entwicklung und Zulassung vieler neuer Medikamente geführt, sodass eine Vielzahl derartiger Kombinationstherapien heutzutage möglich ist und diese auch bei guter Verträglichkeit und mit hoher Lebensqualität durchführbar sind. Die Effektivität der neuen Behandlungsmethoden – insbesondere der neuen Immuntherapien – ist dabei so hoch, dass erstmalig im Rezidiv der Erkrankung tiefe Remissionen ohne Nachweis von minimaler Resterkrankung möglich geworden sind. Diese Entwicklung schreitet unverändert voran, sodass sich auch in Zukunft das Überleben der Patienten weiter verbessern wird.

 

  • Literatur

  • 1 Rajkumar SV, Dimopoulos MA, Palumbo A. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: e538-548
    CrossrefPubMedGoogle Scholar
  • 2 Bruns I, Caddedu RP, Brueckmann I. et al. Multiple myeloma-related deregulation of bone marrow-derived CD34+ hematopietic stem and progenitor cells. Blood 2012; 120: 2620-2630
    CrossrefPubMedGoogle Scholar
  • 3 Dispenzieri A, Katzmann JA, Kyle RA. et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 2010; 375: 1721-1728
    CrossrefPubMedGoogle Scholar
  • 4 Palumbo A, Avet-Loiseau H, Oliva S. et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol 2015; 33: 2863-2869
    CrossrefPubMedGoogle Scholar
  • 5 Kropil P, Fenk R, Fritz LB. et al. Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma. Eur Radiol 2008; 18: 51-58
    CrossrefPubMedGoogle Scholar
  • 6 Cavo M, Terpos E, Nanni C. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 2017; 18: e206-217
    CrossrefPubMedGoogle Scholar
  • 7 Katzmann JA, Clark R, Kyle RA. et al. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia 2013; 27: 208-212
    CrossrefPubMedGoogle Scholar
  • 8 Mateos MV, Lopez JM, Rodrigues-Otero P. et al. Curative strategy for high-risk smoldering myeloma (GEM-CESAR): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HGT-ASCT, consolidation with KRd and maintenance with Rd. Abstract #402. Presented at the 2017 American Society of Hematology Annual Meeting. 10.12.2017. Atlanta, GA:
    CrossrefGoogle Scholar
  • 9 Ghobrial I, Badros AZ, Vredenburgh JJ. et al. Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. Blood 12/2016; 128 (22) 976
    PubMedGoogle Scholar
  • 10 Hofmeister CC, Chari A, Cohen Y. et al. Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study. Blood 2017; 130 (Suppl. 01) 510
    PubMedGoogle Scholar
  • 11 Palumbo A, Bringhen S, Mateos MV. et al. Geriatric assessment predicts survival and toxicities in elderly myeloma: an International Myeloma Working Group report. Blood 2015; 125: 2068-2074
    CrossrefPubMedGoogle Scholar
  • 12 Dhakal B, Chhabra S, Hamadani M. et al. Autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (MM) in the era of novel agents: A meta-analysis of phase III randomized controlled trials. Journal of Clinical Oncology 2017; 35 (15) (suppl) 8022-8022
    CrossrefPubMedGoogle Scholar
  • 13 Neukirchen J, Arat P, Teutloff C. et al. Favourable Outcome of Elderly Patients with Multiple Myeloma Treated with Tandem Melphalan 100 High-Dose Therapy, Autologous Stem Cell Transplantation and Novel Agents – a Single Center Experience. Blood 2016; 128: 3460
    PubMedGoogle Scholar
  • 14 McCarthy PL, Holstein SA, Petrucci MT. et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. J Clin Oncol 2017; 35: 3279-3289
    CrossrefPubMedGoogle Scholar
  • 15 Jackson GH, Davies F, Pawlyn C. et al. Lenalidomide induction and maintenance therapy for transplant eligible myeloma patients: Results of the Myeloma XI study. J Clin Oncol 2017; 35 (15) (suppl) 8009-8009
    CrossrefPubMedGoogle Scholar
  • 16 Fenk R, Giagounidis A, Goldschmidt H. et al. Maintenance therapy (MT) with 25 mg versus 5 mg lenalidomide (Len) after prolonged Len consolidation therapy (CT) in newly-diagnosed, transplant eligible patients (pts) with multiple myeloma (MM). J Clin Oncol. 2018 36. (suppl): abstr 8016
    PubMedGoogle Scholar
  • 17 Benboubker L, Dimopoulos MA, Dispenzieri A. et al. Lenalidomide and Dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014; 371: 906-917
    CrossrefPubMedGoogle Scholar
  • 18 O‘Donnell EK, Laubach JP, Yee AJ. et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol 2018; 182: 222-230
    CrossrefPubMedGoogle Scholar
  • 19 Mateos MV, Dimopoulos MA, Cavo M. et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med 2018; 378: 518-528
    CrossrefPubMedGoogle Scholar
  • 20 Fenk R, Liese V, Neubauer F. et al. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leuk Lymphoma 2011; 52: 1455-1462
    CrossrefPubMedGoogle Scholar
  • 21 Stewart KA, Rajkumar SV, Dimopoulos MA. et al. Carfilzomib, Lenalidomide, and Dexamethason for Relapsed Multiple Myeloma. N Engl J Med 2015; 372: 142-152
    CrossrefPubMedGoogle Scholar
  • 22 Moreau P, Masszi T, Grzasko N. et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 374: 1621-1634
    CrossrefPubMedGoogle Scholar
  • 23 Lonial S, Dimopoulos MA, Palumbo A. et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med 2015; 373: 621-631
    CrossrefPubMedGoogle Scholar
  • 24 Plesner T, Lokhorst H, Gimsing P. et al. Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma – Data From a Dose-Escalation Phase I/II Study. ASH Annual Meeting Abstracts. 16.11.2012 120. 73
    PubMedGoogle Scholar
  • 25 Palumbo A, Chanan-Khan A, Weisel K. et al. Daratumumab, Bortezomib and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 375: 754-766
    CrossrefPubMedGoogle Scholar
  • 26 Dimopoulos MA, Oriol A, Nahi H. et al. Daratumumab, Lenalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 375: 1319-1331
    CrossrefPubMedGoogle Scholar
  • 27 San-Miguel J, Dimopoulos MA, Usmani S. et al. Depth of Response and MRD with Daratumumab Plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM: POLLUX. Clin Lymphoma, Myeloma and Leuk 2017; 17 (Suppl.) e17-e18
    PubMedGoogle Scholar
  • 28 Lacy MQ, Kumar SK, LaPlant BR. et al. Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients. Blood 2012; 120: 201
    PubMedGoogle Scholar
  • 29 Baz R, Martin TG, Alsina M. et al. Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study. Blood 2014; 124: 303
    PubMedGoogle Scholar
  • 30 Richardson PG, Schlussmann RL, Alsina M. et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 2013; 122: 2331-2337
    CrossrefPubMedGoogle Scholar
  • 31 Kumar S, Kaufman JL, Gasparetto C. et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood 2017; 130: 2401-2409
    CrossrefPubMedGoogle Scholar
  • 32 Touzeau C, Maciag P, Amiot M. et al. Targeting Bcl-2 for the treatment of multiple myeloma. Leukemia. 03.08.2018 doi: 10.1038/s41375–018–0223–9. [Epub ahead of print]
    PubMedGoogle Scholar
  • 33 Raje N, Chau I, Hyman DM. Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-independent VE-Basket Study. Blood 2015; 126: 4263
    PubMedGoogle Scholar
  • 34 Raje NS, Berdeja JG, Lin Y. et al. bb2121 anti-BCMA CAR-T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase 1 study. J Clin Oncol. 2018 36. (suppl.) abstr 8007
    PubMedGoogle Scholar